Ticagrelor induced systemic inflammatory response syndrome.

Krisai, Philipp; Haschke, Manuel Martin; Buser, Peter T; Mueller, Christian (2017). Ticagrelor induced systemic inflammatory response syndrome. BMC cardiovascular disorders, 17(1), p. 14. BioMed Central 10.1186/s12872-016-0443-8

Preview

Text s12872-016-0443-8.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (357kB) | Preview

BACKGROUND

Ticagrelor is a reversible and direct-acting oral antagonist of the adenosine diphosphate receptor P2Y12. Possible adenosine-mediated effects of ticagrelor on inflammation are complex and incompletely understood. To our knowledge, ticagrelor-induced systemic inflammatory response syndrome (SIRS) has not yet been described.

CASE PRESENTATION

We report the case of an 84 years old patient presenting with SIRS subsequent to initiation of ticagrelor after implantation of two drug eluting stents. A broad diagnostic work-up for alternative causes and therapeutic measures were unrevealing. Discontinuation of the agent was followed by rapid improvement in clinical and laboratory signs of SIRS.

CONCLUSIONS

After exclusion of other causes, ticagrelor needs to be considered as a possible causative agent for SIRS. Due to the widespread use of ticagrelor, clinicians should be aware of this possible adverse drug reaction.

Interest & Impact

Downloads

155 since deposited on 21 Mar 2018
11 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item